Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Paper
  • Published:

Ibandronate in the treatment of prostate cancer associated painful osseous metastases

Prostate Cancer and Prostatic Diseases volume 5, pages 231–235 (2002)Cite this article

Abstract

The aim of our study was to assess the clinical efficacy and toxicity of ibandronate in the management of symptomatic skeletal metastases due to prostate cancer (PCA). Twenty-five patients with painful osseous metastases due to hormone refractory PCA (HRPCA) were treated with 6 mg ibandronate every 4 weeks in an open prospective non-randomized clinical study. Primary study endpoint was pain reduction documented by the use of a 10-point visual analog scale. Palliative response with significant reduction in pain score from 6.5 (5–10) to 2.0 [(0–4), P<0.001] was achieved in 23 (92%) patients; nine patients (39%) were completely pain free. Bisphosphonate treatment of painful osseous metastases due to HRPCA resulted in a significant pain reduction and a significant decrease of daily consumption of analgesics in 92% of the patients. Both characteristics are paralleled by an increase in Karnofsky index mainly due to better mobility. Bisphosphonates should have a definite role in the palliative management of symptomatic HRPCA.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Parker SL et al. Cancer statistics 1997 CA Cancer J Clin 1997 47: 5

    Article  CAS  PubMed  Google Scholar 

  2. Issacs JT . The biology of hormone refractory prostate cancer Urol Clin North Am 1999 26: 263–273

    Article  Google Scholar 

  3. Smith JA, Soloway MS, Young MJ . Complications of advanced prostate cancer Urology 1999 54: 8–14

    Article  PubMed  Google Scholar 

  4. Clarke NW, McClure J, George NJR . Morphometric evidence for bone resorption and replacement in prostate cancer Br J Urol 1991 68: 74–80

    Article  CAS  PubMed  Google Scholar 

  5. Body JJ et al. Current use of bisphosphonates in oncology J Clin Oncol 1998 16: 3890–3899

    Article  CAS  PubMed  Google Scholar 

  6. Heidenreich A et al. The use of bisphosphonates for the palliative treatment of painful bone metastases due to hormone refractory prostate cancer J Urol 2001 165: 136–140

    Article  CAS  PubMed  Google Scholar 

  7. Mühlbauer RC et al. BM 21.0955, a potent new bisphosphonate to inhibit bone resorption J Bone Mineral Res 1991 6: 1003–1011

    Article  Google Scholar 

  8. Fleisch H . Bisphosphonates in Bone Disease Stampfli, Berne 1993

    Google Scholar 

  9. Lang SH et al. Scatter factor influences the formation of prostate epithelial cell colonies on bone marrow stromain vitro Clin Exp Metas 1999 17: 333–340

    Article  CAS  Google Scholar 

  10. Lang SH et al. The interaction of prostatic epithelia with human bone marrow stroma Prostate 1998 34: 203–213

    Article  CAS  PubMed  Google Scholar 

  11. Purohit P et al. High dose intravenous pamidronate for metastastic bone pain Br J Cancer 1994 70: 554–558

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Ernst DS et al. A randomized controlled trial of intravenous clodronate in patients with metastatic bone disease and pain J Pain Symptom Manage 1997 13: 319–326

    Article  CAS  PubMed  Google Scholar 

  13. Adami S et al. Dichloromethylene diphosphonate in patients with carcinoma of the prostate metastatic to the skeleton J Urol 1985 134: 1152–1154

    Article  CAS  PubMed  Google Scholar 

  14. Smith JA . Palliation of painful bone metastases from prostate cancer using sodium etidornate: results of randomised, prospective placebo controlled study J Urol 1989 141: 85–87

    Article  PubMed  Google Scholar 

  15. Clarke NW, McClure J, George NJR . Disodium pamidronate identifies differential osteoclastic bone resorption in metastatic prostate cancer Br J Urol 1992 69: 64–68

    Article  CAS  PubMed  Google Scholar 

  16. Cresswell S et al. Pain relief and quality of life assessment following intravenous and oral clodronate in hormone escaped prostate cancer Br J Urol 1995 76: 360–365

    Article  CAS  PubMed  Google Scholar 

  17. Harvey A et al. The role of bisphosphonates in the treatment of bone metastases—the US experience Support Care Cancer 1996 4: 213–217

    Article  CAS  PubMed  Google Scholar 

  18. Kylmala T et al. The effect of combined and oral clodronate on bone pain in patients with metastastatic prostate cancer Ann Chir Gynaecol 1994 83: 316–319

    CAS  PubMed  Google Scholar 

  19. Vorreuther R . Bisphosphonates as an adjunct to palliative therapy in patients with metastases from prostate carcinoma. A pilot study on clodronate Br J Urol 1993 72: 792–795

    Article  CAS  PubMed  Google Scholar 

  20. Ralston SH . Pathogenesis and management of hypercalcaemia In: Rubens RD, Fogelman I (eds) Bone Metastases: Diagnosis and Treatment Springer Verlag, London 1991 pp 99–117

    Google Scholar 

  21. Ralston SH et al. Dose-response study of ibandronate in the treatment of cancer-associated hypercalcaemia Br J Cancer 1997 75: 295–300

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Gallacher SJ et al. Breast cancer associated hypercalcaemia: a reassessment of renal calcium and phosphate handling Ann Clin Biochem 1990 27: 551–556

    Article  PubMed  Google Scholar 

  23. Grill V et al. Parathyroid hormone related protein: elevated levels in both humoral hypercalcaemia of malignancy and hypercalcaemia complicating breast cancer J Clin Endocrinol Metab 1991 73: 1309–1315

    Article  CAS  PubMed  Google Scholar 

  24. Urwin GH et al. Generalised increase in bone resorption in carcinoma of the prostate Br J Urol 1985 57: 721

    Article  CAS  PubMed  Google Scholar 

  25. Clarke NW, McClure J, George NJR . Osteoblastic function and osteomalacia in metastatic prostate cancer Eur Urol 1993 24: 286

    Article  CAS  PubMed  Google Scholar 

  26. Taube T et al. Distinction between focally accelerated bone formation and osteomalacia in carcinoma of prostate metastasised to bone Br J Urol 1993 72: 98

    Article  CAS  PubMed  Google Scholar 

  27. Bichler K-H et al. Investigations on bone metabolism of urological tumors forming metastases Urol Int 1996 56: 61–68

    Article  CAS  PubMed  Google Scholar 

  28. Tannock IF et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone resistant prostate cancer: a Canadian randomized trial with palliative endpoints J Clin Oncol 1996 14: 1756

    Article  CAS  PubMed  Google Scholar 

  29. Kanthoff PW et al. Hydrocortisone with or without mitoxantrone in men with hormone refractory prostate cancer: results of the cancer and leukemia group B 9182 study J Clin Oncol 1999 17: 2506

    Article  Google Scholar 

  30. Biossier S et al. Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases Cancer Res 2000 60: 2949–2954

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, Philipps - University Marburg, Baldingerstrasse, Marburg, Germany

    A Heidenreich, A Elert & R Hofmann

Authors
  1. A Heidenreich
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A Elert
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. R Hofmann
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A Heidenreich.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Heidenreich, A., Elert, A. & Hofmann, R. Ibandronate in the treatment of prostate cancer associated painful osseous metastases. Prostate Cancer Prostatic Dis 5, 231–235 (2002). https://doi.org/10.1038/sj.pcan.4500574

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.pcan.4500574

Keywords

This article is cited by

Search

Advanced search

Quick links